Related Articles
Rheumatology Drug Updates, Trials, Safety Data
Information on oral anticoagulant apixaban, apremilast for active psoriatic arthritis, hyaluronic acid and methotrexate injections, and drug safety updates rheumatologists need to know
Case Report: A Patient on Apremilast Develops Streptococcus Salivarius
Apremilast was first marketed in March 2014 for the treatment of adults with psoriatic arthritis (PsA). An immunomodulating drug, which is a small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP), apremilast is administered orally. By inhibiting PDE4, intracellular cAMP levels are increased. Although the exact mechanism of action is not…
Rheumatology Drug Updates: Biosimilars Receive Positive News & More
On Nov. 19, 2015, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for SB4, an etanercept biosimilar product that will be called Benepali.1 On Jan. 16, 2016, EMA granted marketing authorization in the European Union for Benepali to be used to treat rheumatoid arthritis (RA), psoriatic…
Drug Updates: Apremilast, Belimumab, and More
Information on new approvals and medication safety